Eleven investigators will receive a total of $700,000 in funding for new cancer research projects through Winship Invest$.
Eleven investigators will receive a total of $700,000 in funding for new cancer research projects through Winship Invest$, a peer-reviewed program designed to fund novel, innovative cancer research at Winship Cancer Institute of Emory University.
Winship Invest$ is supported by philanthropic contributions as well as developmental funds from Winship's Cancer Center Support Grant (P30CA138292) awarded by the National Cancer Institute of the National Institutes of Health.
Winship Invest$ has two funding cycles every year and solicits proposals in strategic research domains. The most recent call for proposals focused on projects related to team science, early-career investigators, and Winship's four research programs.
This cycle's Winship Invest$ pilot grant recipients are below.
- Adaptive immune responses to COVID-19 and influenza vaccine in patients with lymphoma
Andres Chang, MD, PhD - Molecular Imaging of the Hypoxic Tumor Microenvironment to Predict Response to Yttrium-90 Selective Internal Radiation Therapy in Hepatocellular Carcinoma
Nima Kokabi, MD - Development of a pancreatic cancer no viral delivery system
Leon Bernal-Mizrachi, MD - Investigating the oncogenic roles of AMPK in LKB1-mutant LUAD
Melissa Gilbert-Ross, PhD - Mechanisms of chemotherapy resistance in SMARCB1-deficient childhood cancers
Andrew Hong, MD - A Technology-Based Colorectal Cancer Information Coaching/Support Program for Asian American Women
Eun-Ok Im, PhD, MPH, RN, CNS, FAAN - Biomarker-Based Approaches to Understand and Predict Cardiovascular Toxicity from Androgen Deprivation Therapy Targeting the Gonadotropin Releasing Hormone Pathway
Brian Olson, PhD - Enhanced Abscopal Responses with IAP Antagonism
Nicole Schmitt, MD - General Modulating Mitochondrial Dynamics to Enhance Therapeutic T Cell Expansion and Persistence
Mala Shanmugam, PhD - A Phase I study of subcutaneously administered natural progesterone for the treatment of recurrent GBM
Hui-Kuo Shu, MD, PhD - Targeting FGFR4 signaling to potentiate antitumor immunity
Yong Teng, PhD
